ELU001 in Pediatric Subjects Who Have Relapsed and/or Refractory CBFA2T3-GLIS2-positive AML

Key Inclusion Criteria: Patients must meet the following criteria to enroll in this study: * Infants (\>1 month) and children (≤9 years) at time of enrollment. * Relapsed or refractory CBFA2T3::GLIS2 positive AML * CNS1 or CNS2 during screening * Performance Status: Lansky ≥ 50 * Adequate Organ Function including liver, kidney, and heart Key Exclusion Criteria: Patients who meet any of the following are not eligible to enroll in this study: * CNS3 Disease * AML associated with congenital syndromes such as Down syndrome, Fanconi anemia, Bloom syndrome, Kostmann syndrome or Diamond-Blackfan anemia, or bone marrow failure associated with inherited syndromes. * Acute promyelocytic leukemia. * Clinically significant active or chronic corneal disorder, particularly corneal epitheliopathy or any eye disorder that may predispose patient to this condition, or unable to comply with an age-appropriate ophthalmologic examination. * Prior treatment with folate receptor-targeting anti-cancer agent(s) ≤ 21 days (or 2 half-lives must have elapsed before enrollment, whichever is longer), or received investigational anti-cancer treatment ≤ 4 weeks, or within a time interval less than at least 5 half-lives of the investigational agent, prior to starting study drug, whichever is shorter.